Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


Purpose:

To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alveolar macrophages in AIDS patients.


Criteria:

Inclusion Criteria Patients must have: - Diagnosis of AIDS with one or more opportunistic infections. - Kaposi's sarcoma with prior history of opportunistic infection. - Stable dose of zidovudine (AZT) therapy. - Preserved pulmonary, renal and hepatic function. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Presence of active infection. - Active opportunistic infections. - Cardiac disease. - Central nervous system disorders. - History of seizures. - Irreversible airway disease. Patients with the following are excluded: - Co-existing conditions and symptoms listed in Patient Exclusion Co-existing Conditions. Prior Medication: Excluded within 4 weeks of study entry: - Immunosuppressive therapy. - Cytotoxic therapy. - Excluded: - Interferon gamma therapy.


NCT ID:

NCT00002433


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

New York, New York 10021
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.